Editorial
Looking back at genomic medicine in 2011
-
* Corresponding author: Charles Auffray auffray@vjf.cnrs.fr
- † Equal contributors
1 CNRS Institute of Biological Sciences, European Institute for Systems Biology & Medicine, Claude Bernard University, 69007 Lyon, France
2 Faculty of Law and School of Public Health, 461 Law Centre, University of Alberta, Edmonton, T6G 2H5, Canada
3 Office of Public Health Genomics, Centers for Disease Control and Prevention, 1600 Clifton Rd, NE, MS E61, Atlanta, GA 30333, USA
4 Departments of Molecular and Human Genetics and Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA
5 Texas Children's Hospital, Houston, TX 77030, USA
6 Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Auerbach Str. 112, 70367 Stuttgart, Germany
7 Department of Clinical Pharmacology, Institute of Experimental and Clinical Pharmacology and Toxicology, University Hospital, 72076 Tübingen, Germany
8 Laboratory of Proteomics and Analytical Technologies, National Cancer Institute at Frederick, Frederick, MD 21702-1201, USA
Genome Medicine 2012, 4:9 doi:10.1186/gm308
Published: 30 January 2012First paragraph (this article has no abstract)
Genomic medicine, in its broadest sense of being medical developments informed by 'omic' advances, has continued to move towards the clinic in 2011. To mark the end of the year and the beginning of 2012, the editors of the six sections within Genome Medicine were invited to provide their highlights of the past year and to hint at the developments that we are likely to see in the near future.